NCT06999031View on ClinicalTrials.gov

A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 5, 2024

Primary Completion Date

April 5, 2026

Study Completion Date

September 30, 2027

Conditions
Relapsed/RefractoryMultiple Myeloma
Interventions
BIOLOGICAL

BCMA-Targeted Chimeric Antigen Receptor Autologous T-cell

Chimeric Antigen Receptor Autologous T-cell

Trial Locations (1)

330200

RECRUITING

The First Affiliated Hospital of Nanchang University, Nanchang

All Listed Sponsors
collaborator

Cells & Genes Biotech (Shanghai) Co.,Ltd

INDUSTRY

lead

The First Affiliated Hospital of Nanchang University

OTHER